Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Serious adverse events · adults with chronic neuropathic pain
1 finding from 1 review
Serious adverse events · children with acute postoperative pain
1 finding from 1 review
Serious adverse events · children with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes serious adverse events compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Serious adverse events · post‐prostatectomy erectile dysfunction (short‐term)
Scheduled PDE5I may leads to lower serious adverse events compared with on demand placebo or no treatment (low certainty).
1 finding from 1 review
Serious adverse events ( · children with either displaced distal radius fracture with intact or displaced ulna fracture (both‐bone fracture), or minimally displaced…
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).
1 finding from 1 review
Serious adverse events · cancer patients
Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.46 [0.48, 12.55]
Studies not reported
Low
Serious adverse events · cancer patients
It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).
1 finding from 1 review
RR 0.33 [0.02, 7.32]
Studies not reported
Very low
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
1 finding from 1 review
Serious adverse events · people with Child‐Pugh stage A or B cirrhosis
Exercise showed no clear difference in serious adverse events compared with no exercise (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review